MARKERS OF ENDOMETRIAL CANCER

The present invention provides a method of diagnosis or prognosis endometrial carcinoma, the method comprising determining the level of expression of one or more proteins selected from the group consisting of: CLIC1, ANXA1, ANXA2, CAPG, CAYP1, CASP3, CD44, CADH1, XPO2, CTNB1, ENOA, FABP5, GSTP1, HSP...

Full description

Saved in:
Bibliographic Details
Main Authors GIL MORENO, Antonio, MARTINEZ GARCÍA, Elena, REVENTÓS PUIGJANER, Jaume, DOMON, Bruno, LESUR, Antoine, COLAS ORTEGA, Eva
Format Patent
LanguageEnglish
French
German
Published 17.05.2023
Subjects
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
PHYSICS
TESTING
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a method of diagnosis or prognosis endometrial carcinoma, the method comprising determining the level of expression of one or more proteins selected from the group consisting of: CLIC1, ANXA1, ANXA2, CAPG, CAYP1, CASP3, CD44, CADH1, XPO2, CTNB1, ENOA, FABP5, GSTP1, HSPB1, CH10, K2C8, NGAL, LDHA, MIF, MMP9, MUC1, NAMPT, PIGR, KPYM, PRDX1, SG2A1, GTR1, SPIT1, OSTP, TPIS and PDIA1, in an isolated fluid sample from the female genital tract..The present invention further provides kits for the diagnosis of the disease.
Bibliography:Application Number: EP20230150361